Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498836 · ClinicalTrials.gov registry record · Phase 2
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
A Phase 2 study, sponsored by Clavis Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00498836 is a Phase 2 study that has completed, run by Clavis Pharma. The registered enrollment target is 18 participants.
The verdict
NCT00498836, a Phase 2 study, has completed, sponsored by Clavis Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Patients with metastatic malignant melanoma will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5 every four weeks and sorafenib 400 mg b.i.d. (twice daily) every day until complete response or disease worsening/progressing.
Interventions
- DRUG CP-4055
- DRUG Sorafenib (Nexavar)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00498836
The ClinicalTrials.gov registry entry for NCT00498836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clavis Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CP-4055 is the first listed.
NCT00498836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00498836 about?
NCT00498836 is a clinical study titled "Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma". Patients with metastatic malignant melanoma will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5 every four weeks and sorafenib 400 mg b.i.d. (twice daily) every day until complete response or disease worsening/progressing.
What is the current status of trial NCT00498836?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2007-03. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00498836?
The interventions under investigation include: CP-4055 (DRUG), Sorafenib (Nexavar) (DRUG).
Who is sponsoring clinical trial NCT00498836?
This trial is sponsored by Clavis Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.